Screener
Kailera Therapeutics KLRA Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Series A convertible preferred stock: $0.00001 par value; 35,677,603 shares authorized at March 31, 2026 and December 31, 2025; 35,677,603 shares issued and outstanding at March 31, 2026 and December 31, 2025; liquidation value of $356.8 million at March 31, 2026 | 390,306 | 390,306 |
| Series B convertible preferred stock: $0.00001 par value; 43,084,539 shares authorized at March 31, 2026 and December 31, 2025; 43,084,539 shares issued and outstanding at March 31, 2026 and December 31, 2025; liquidation value of $603.2 million at March 31, 2026 | 602,058 | 602,058 |
| Stockholders’ deficit: | ||
| Common stock, $0.00001 par value; 105,384,000 shares authorized at March 31, 2026 and December 31, 2025; 29,953 and 19,048 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid-in capital | 15,977 | 11,981 |
| Accumulated other comprehensive (loss) income | (532) | 229 |
| Accumulated deficit | (447,533) | (368,668) |
| Total stockholders’ deficit | (432,088) | (356,458) |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's common stock?
- Kailera Therapeutics (KLRA) reported common stock of $0 in Q1 2026.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Kailera Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude